Literature DB >> 28667012

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).

Fleur Cohen Aubart1,2, Jean-François Emile3,4, Fabrice Carrat2,5,6, Frédéric Charlotte2,7, Neila Benameur8, Jean Donadieu9, Philippe Maksud10, Ahmed Idbaih11, Stéphane Barete12, Khê Hoang-Xuan11, Zahir Amoura1,2, Julien Haroche1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28667012     DOI： 10.1182/blood-2017-03-771873

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  41 in total

1.  Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition.

Authors:  Olive S Eckstein; Johannes Visser; Carlos Rodriguez-Galindo; Carl E Allen
Journal:  Blood       Date:  2019-02-04       Impact factor: 22.113

2.  Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.

Authors:  Anaïs Roeser; Fleur Cohen-Aubart; Paul Breillat; Makoto Miyara; Jean-François Emile; Frédéric Charlotte; Jean Donadieu; Zahir Amoura; Julien Haroche
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

Review 3.  Erdheim-Chester disease: a rapidly evolving disease model.

Authors:  Francesco Pegoraro; Matthias Papo; Valerio Maniscalco; Frédéric Charlotte; Julien Haroche; Augusto Vaglio
Journal:  Leukemia       Date:  2020-06-26       Impact factor: 11.528

4.  Low-dose vemurafenib monotherapy in BRAFV600E -mutated Erdheim-Chester disease.

Authors:  Gordon J Ruan; Antonious Hazim; Jithma P Abeykoon; Caleb Scheckel; Robert Vassallo; Jay H Ryu; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Karen L Rech; Jason R Young; Mithun V Shah; Gaurav Goyal; Ronald S Go
Journal:  Leuk Lymphoma       Date:  2020-07-01

5.  Highly sensitive methods are required to detect mutations in histiocytoses.

Authors:  Sarah Melloul; Zofia Hélias-Rodzewicz; Fleur Cohen-Aubart; Frédéric Charlotte; Sylvie Fraitag; Nathalie Terrones; Quentin Riller; Thibaud Chazal; Sébastien Héritier; Anne Moreau; Marianne Kambouchner; Marie Christine Copin; Jean Donadieu; Valérie Taly; Zahir Amoura; Julien Haroche; Jean François Emile
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

Review 6.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

Review 7.  Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.

Authors:  Matthias Papo; Fleur Cohen-Aubart; Ludovic Trefond; Adeline Bauvois; Zahir Amoura; Jean-François Emile; Julien Haroche
Journal:  Curr Oncol Rep       Date:  2019-05-21       Impact factor: 5.075

8.  Efficacy of BRAF-Inhibitor Therapy in BRAFV600E -Mutated Adult Langerhans Cell Histiocytosis.

Authors:  Antonious Z Hazim; Gordon J Ruan; Aishwarya Ravindran; Jithma P Abeykoon; Caleb Scheckel; Robert Vassallo; Jay H Ryu; W Oliver Tobin; Matthew J Koster; N Nora Bennani; Karen L Rech; Jason R Young; Mithun V Shah; Gaurav Goyal; Ronald S Go
Journal:  Oncologist       Date:  2020-10-12

Review 9.  Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Authors:  Oussama Abla; Eric Jacobsen; Jennifer Picarsic; Zdenka Krenova; Ronald Jaffe; Jean-Francois Emile; Benjamin H Durham; Jorge Braier; Frédéric Charlotte; Jean Donadieu; Fleur Cohen-Aubart; Carlos Rodriguez-Galindo; Carl Allen; James A Whitlock; Sheila Weitzman; Kenneth L McClain; Julien Haroche; Eli L Diamond
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

10.  From inflammation to cancer: entering a new frontier in the management of Erdheim-Chester disease.

Authors:  Lakshmi Nayak
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.